Healthcare >> CEO Interviews >> April 9, 2001
DANIEL VASELLA, MD, is Chairman and Chief Executive Officer of Novartis
AG. He assumed the position of Chairman in April 1999, having served as
President and Head of the Executive Committee since the merger in 1996.
Before the Novartis merger, Dr. Vasella was Chief Executive Officer of
Sandoz Pharma Ltd. In this capacity, he was responsible for managing all
pharmaceutical activities of the Sandoz Group worldwide. Additionally,
he was a member of the Sandoz Group Executive Committee. Prior to his
appointment as CEO of Sandoz Pharma, Dr. Vasella was Chief Operating
Officer of Sandoz Pharma and, before that, Senior Vice President and
Head of Worldwide Development. In 1993, Dr. Vasella was Head of
Corporate Marketing. From 1988 to 1992, he was with Sandoz
Pharmaceuticals Corporation in the US. There he moved from Market
Research and Sales to Product Manager for Sandostatin', and then to
Director of Special Project Marketing. Before joining Sandoz, Dr.
Vasella held a number of medical positions in Switzerland. From 1984 to
1988, he was Attendant Physician at C.L. Lory Haus, University Hospital,
Bern. Prior to this, he held residencies at Waid Hospital in Zurich,
University Hospital, Bern and at the University of Bern Institute of
Pathology. Profile
Novartis?
Dr. Vasella: Novartis is today a company focused on health care, with
pharmaceuticals as its core, with over
